<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143256</url>
  </required_header>
  <id_info>
    <org_study_id>PROT-00109</org_study_id>
    <nct_id>NCT04143256</nct_id>
  </id_info>
  <brief_title>Evaluating Selected Constituents in the Exhaled Breath Samples</brief_title>
  <official_title>An Open-Label, Multi-Center Study to Evaluate Selected Constituents in the Exhaled Breath Samples From the Use of JUUL Nicotine Salt Pod System Product (5% and 3% Virginia Tobacco, Mint, Mango, Menthol) Users and Conventional Cigarettes (Non-Menthol and Menthol Flavors)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juul Labs, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Juul Labs, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label, Multi-Center Study to Evaluate Selected Constituents in the Exhaled Breath&#xD;
      Samples From the Use of JUUL Nicotine Salt Pod System Product (5% and 3% Virginia Tobacco,&#xD;
      Mint, Mango, Menthol) Users and Conventional Cigarettes (Non-Menthol and Menthol Flavors)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the baseline-adjusted level of selected&#xD;
      constituents in the exhaled breath sample (EBS) between the two JUUL NSPS products (5% vs 3%&#xD;
      nicotine by weight) for Virginia Tobacco, Mint, Mango and Menthol flavor and to compare the&#xD;
      change in absolute level of selected constituents in EBS before and after the use of JUUL&#xD;
      NSPS (5% and 3% nicotine by weight; Virginia Tobacco, Mint, Mango, Menthol flavors) to the&#xD;
      change in absolute level of selected constituents before and after the use of menthol and&#xD;
      non-menthol cigarettes.&#xD;
&#xD;
      Subjects will be screened for participation in the trial up to 28 days before Day 1. Along&#xD;
      with screening procedures, all subjects will receive training on EBS collection procedures.&#xD;
      All subjects will be further trained on the CPS using a training video and site instructions.&#xD;
      Trained subjects will have the opportunity to try the JUUL NSPS.&#xD;
&#xD;
      Eligible subjects will be scheduled for a Day 1 clinic visit. Within 24 to 48 hours prior to&#xD;
      Check-in, the clinic staff will provide a courtesy phone call to subjects to remind them to&#xD;
      abstain from the use of alcohol, any nicotine-containing products and mint/mentholated&#xD;
      products for at least 12 hours prior and xanthines/caffeine for at least 24 hours prior to&#xD;
      screening and Day 1.&#xD;
&#xD;
      Following completion of the check-in events, including re-instruction on the EBS sample&#xD;
      collection technique and CPS instructions, subjects will participate in the exhaled breath&#xD;
      collection test sessions.&#xD;
&#xD;
      Groups I - IV will complete two periods of baseline and test sample collections with a 3-hour&#xD;
      break in between each period. Each period will consist of two baseline samples (the first for&#xD;
      analysis of nicotine, propylene glycol and glycerin and the second for analysis of&#xD;
      acetaldehyde, acrolein, benzoic acid, formaldehyde, and menthol), followed by product use,&#xD;
      and then two test samples (similar to baseline). Exhaled CO will be measured before the first&#xD;
      baseline sample, after the second baseline sample, before the first test sample and after the&#xD;
      second test sample. Pods used during the test sessions will be weighed before and after use.&#xD;
&#xD;
      Groups V and VI will complete only one period of baseline and test sample collections,&#xD;
      consisting of two baseline sample collections and two test sample collections similar to that&#xD;
      noted above.&#xD;
&#xD;
      A follow-up phone call with subjects will be made the day after Check-out (or early&#xD;
      withdrawal). Provided there are no adverse events which require further attention, the&#xD;
      subject's participation in the trial will be complete.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 3, 2019</start_date>
  <completion_date type="Actual">December 13, 2019</completion_date>
  <primary_completion_date type="Actual">December 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Four crossover groups and two single arm groups</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of nicotine for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of propylene glycol for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of vegetable glycerin for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of acetaldehyde for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of acrolein for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of benzoic acid for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of formaldehyde for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of menthol for each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Absolute Change from Baseline Level</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>The absolute change from baseline level of carbon monoxide for each subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of nicotine for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of propylene glycol for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of vegetable glycerin for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of acetaldehyde for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of acrolein for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of benzoic acid for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of formaldehyde for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of menthol for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change between baseline and post-baseline levels</measure>
    <time_frame>Up to 6-hours</time_frame>
    <description>Compare the change between baseline and post-baseline levels of carbon monoxide for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>Up to 45</time_frame>
    <description>Change in the weight of JUUL pods before and after the usage.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Electronic Cigarette Use</condition>
  <condition>Cigarette Use, Electronic</condition>
  <condition>Tobacco Use</condition>
  <condition>Tobacco Smoking</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Virginia Tobacco and 3% Virginia Tobacco</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mint and 3% Mint</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Menthol and 3% Menthol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mango and 3% Mango</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with cigarette user history will be assigned to use US Cigarette, Non-Menthol Flavor (Marlboro Gold King Size)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group VI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with cigarette user history will be assigned to use US Cigarette, Menthol Flavor (Newport King Size)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL ENDS 5% Virginia Tobacco</intervention_name>
    <description>JUUL ENDS Virginia Tobacco 5% nicotine strength</description>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL 3% Virginia Tobacco ENDS</intervention_name>
    <description>JUUL ENDS Virginia Tobacco 3% nicotine strength</description>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL 5% Mint ENDS</intervention_name>
    <description>JUUL ENDS Mint 5% nicotine strength</description>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL 3% Mint ENDS</intervention_name>
    <description>JUUL ENDS Mint 3% nicotine strength</description>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL 5% Menthol ENDS</intervention_name>
    <description>JUUL ENDS Menthol 5% nicotine strength</description>
    <arm_group_label>Group III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL 3% Menthol ENDS</intervention_name>
    <description>JUUL ENDS Menthol 3% nicotine strength</description>
    <arm_group_label>Group III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL 5% Mango ENDS</intervention_name>
    <description>JUUL ENDS Mango 5% nicotine strength</description>
    <arm_group_label>Group IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL 3% Mango ENDS</intervention_name>
    <description>JUUL ENDS Mango 3% nicotine strength</description>
    <arm_group_label>Group IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>US Cigarette, Non-menthol - Marlboro Gold King Size</intervention_name>
    <description>US Cigarette, Non-menthol - Marlboro Gold King Size</description>
    <arm_group_label>Group V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>US Cigarette, Menthol - Newport King Size</intervention_name>
    <description>US Cigarette, Menthol - Newport King Size</description>
    <arm_group_label>Group VI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be a healthy male or female aged 21 - 65 years, inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          2. Be informed of the nature of the study, agree to and are able to read, review, and&#xD;
             sign the informed consent document prior to any study procedures. The informed consent&#xD;
             document will only be available in English. Therefore, the volunteer must have the&#xD;
             ability to read and communicate in English in order to participate in the study.&#xD;
&#xD;
          3. Complete the screening process up to 28 days prior to Day 1.&#xD;
&#xD;
          4. Satisfy the user definitions of either cigarette user or ENDS/closed system user.&#xD;
&#xD;
          5. Agree to abide by the study restrictions.&#xD;
&#xD;
          6. Agree to abstain from use of alcohol 12 hours before the start of Day 1 for Groups I&#xD;
             through VI.&#xD;
&#xD;
          7. Agree to abstain from use of any nicotine products 12 hours before the start of study&#xD;
             day 1 for Groups I through VI.&#xD;
&#xD;
          8. Agree to not consume any mint or menthol flavor products (e.g., chewing gum, mouth&#xD;
             wash, toothpaste, etc.) 12 hours before the start of testing for Groups I through VI.&#xD;
&#xD;
          9. Have a positive urine cotinine result at screening of &gt;200 ng/ml.&#xD;
&#xD;
         10. A female subject of childbearing potential must have been using one (1) of the&#xD;
             following forms of contraception and agree to continue using it through completion of&#xD;
             the trial:&#xD;
&#xD;
               -  hormonal (e.g., oral, vaginal ring, transdermal patch, implant, or injection)&#xD;
                  consistently for at least 3 months prior to Day 1;&#xD;
&#xD;
               -  double barrier method (e.g., condom with spermicide, diaphragm with spermicide)&#xD;
                  at screening.&#xD;
&#xD;
               -  intrauterine device for at least 3 months prior to Day 1;&#xD;
&#xD;
               -  a partner who has been vasectomized for at least 6 months prior to Day 1;&#xD;
&#xD;
               -  abstinence beginning at least 6 months prior to screening.&#xD;
&#xD;
         11. A female subject of non childbearing potential must have undergone one of the&#xD;
             following sterilization procedures at least 6 months prior to Day 1:&#xD;
&#xD;
               -  hysteroscopic sterilization;&#xD;
&#xD;
               -  bilateral tubal ligation or bilateral salpingectomy;&#xD;
&#xD;
               -  hysterectomy;&#xD;
&#xD;
               -  bilateral oophorectomy;&#xD;
&#xD;
               -  Or be postmenopausal with amenorrhea for at least 1 year prior to Day 1.&#xD;
&#xD;
         12. Be judged by the Investigator to be in good general health as documented by the&#xD;
             medical history, physical examination (including but may not be limited to an&#xD;
             evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous&#xD;
             systems), vital sign assessments and by general observations. Any abnormalities or&#xD;
             deviations outside the normal ranges for any clinical testing (e.g. vital signs) can&#xD;
             be repeated at the discretion of the Investigator and judged to be not clinically&#xD;
             significant for study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Report receiving any investigational product, participated in any previous clinical&#xD;
             study for an investigational drug, device, biologic, or tobacco product within 30 days&#xD;
             prior to screening.&#xD;
&#xD;
          2. Report at screening using both ENDS and conventional cigarettes (menthol or&#xD;
             non-menthol) (dual users), or use of other inhaled products (such as, but not limited&#xD;
             to cannabis) in the past 3 months.&#xD;
&#xD;
          3. For ENDS users, be unable to perform CPS or incapable of drawing down the pod weight&#xD;
             by 20-60mg after 3 attempts at screening.&#xD;
&#xD;
          4. If female, be pregnant, have a positive urine pregnancy test at screening, be&#xD;
             lactating, breast feeding, or intend to become pregnant during the time period from&#xD;
             screening through the end of the study.&#xD;
&#xD;
          5. Have any clinically significant results from physical examinations and vital signs&#xD;
             assessments, as judged by the Investigator.&#xD;
&#xD;
          6. Have a systolic blood pressure &lt; 90 mmHg or &gt; 150 mmHg, diastolic blood pressure &lt; 40&#xD;
             mmHg or &gt; 95 mmHg, or heart rate &lt; 40 bpm or &gt; 99 bpm at screening.&#xD;
&#xD;
          7. Report a clinically significant illness during the 30 days prior to enrollment, as&#xD;
             determined by the Investigator.&#xD;
&#xD;
          8. Report a history of drug or alcohol addiction or abuse within the past 1 year.&#xD;
&#xD;
          9. Have a positive screen for alcohol or drugs of abuse at screening or at check-in on&#xD;
             Day 1.&#xD;
&#xD;
         10. Have a body mass index (BMI) greater than 40 kg/m2 or less than 18 kg/m2 at screening.&#xD;
&#xD;
         11. Have used prescription anti-diabetic medication and/or insulin therapy within 12&#xD;
             months of screening.&#xD;
&#xD;
         12. Have taken medication for depression, asthma, or chronic obstructive pulmonary disease&#xD;
             within 6 months of screening.&#xD;
&#xD;
         13. Have used prescription or over-the-counter bronchodilator medication (e.g., inhaled or&#xD;
             oral Î²-agonists) within 6 months of screening.&#xD;
&#xD;
         14. Be breast-feeding or pregnant female subjects (confirmed by a positive pregnancy&#xD;
             test). Female subjects, who are considered women of child bearing potential (WOCBP)&#xD;
             and sexually active, must be willing and able to use an acceptable method of&#xD;
             contraception from screening through the end of the study.&#xD;
&#xD;
         15. Have experienced an allergic reaction following previous e-cigarette use or with&#xD;
             exposure to any primary components of the e-liquids (nicotine, flavor, benzoic acid,&#xD;
             propylene glycol, and/or glycerol.&#xD;
&#xD;
         16. Be or have a first-degree relative (i.e. parent, sibling or child) who is a current&#xD;
             employee of CRO, Sponsor, or site.&#xD;
&#xD;
         17. In the opinion of an Investigator, be deemed not eligible to participate in this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Frontage Clinical Services</name>
      <address>
        <city>Secaucus</city>
        <state>New Jersey</state>
        <zip>07094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rose Research Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rose Research Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electronic Nicotine Delivery</keyword>
  <keyword>Combustible Cigarettes</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Exhaled Breath</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

